|Title:||Arguments in favour of remdesivir for treating SARS-CoV-2 infections||Authors:||Ko W.-C.
|Issue Date:||2020||Start page/Pages:||105933||Source:||International Journal of Antimicrobial Agents||URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/479659||ISSN:||0924-8579||DOI:||10.1016/j.ijantimicag.2020.105933||SDG/Keyword:||[SDGs]SDG3
aciclovir; aristeromycin; favipiravir; galidesivir; penciclovir; remdesivir; ribavirin; RNA directed RNA polymerase; adenosine phosphate; alanine; antivirus agent; DNA directed RNA polymerase; remdesivir; amino acid substitution; antibiotic resistance; antiviral activity; clinical effectiveness; concentration response; coronavirus disease 2019; coronavirus disease 2019; Coronavirus infection; drug half life; drug tolerability; Ebola hemorrhagic fever; Editorial; human; nonhuman; priority journal; protein targeting; SARS-related coronavirus; Severe acute respiratory syndrome coronavirus 2; treatment outcome; treatment response; virus load; animal; Betacoronavirus; clinical trial (topic); Coronavirus infection; drug effect; enzymology; pandemic; virus pneumonia; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; DNA-Directed RNA Polymerases; Humans; Pandemics; Pneumonia, Viral
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.